Are Automation and AI the Future of Brain Scan Analysis?

After decades of development work, and trial and error and money spent, you might think that by the time your head is put inside a magnetic resonance imaging (MRI) scanner at a hospital, the difficult part of looking inside the brain is finished. But often it’s the analysis that comes after you leave the scanner that proves most challenging for physicians. The error rate for image analysis remains alarmingly high, and radiologists are being asked to handle and process larger numbers of scans every year. Can automation lend a hand? We talked to Dr. Chris Airriess, CEO at CorTechs Labs Inc., which has developed a post-processing scan software called NeuroQuant designed to streamline the analysis pipeline. We asked Chris about the current challenges in analysis, what datasets NeuroQuant would be trained on, and whether the general public will trust their medical scans to an AI.

Spotlight

Drug Discovery Center of Innovation

The Drug Discovery Center of Innovation (DDCOI) provides pharmaceutical expertise and project management resources to accelerate the translation of discoveries into therapeutics. We offer a non-profit alternative to more traditional approaches to early drug development, with a focus on cost-efficient execution of development tasks, rather than the creation of infrastructure. Our deep pharmaceutical development experts establish and manage project plans, and provide end-to-end data analysis and troubleshooting to facilitate the creation of a successful application for IND and beyond.

OTHER ARTICLES
MedTech

5 Biotech Stocks Winning the Coronavirus Race

Article | July 12, 2022

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More
MedTech

Expansion of BioPharma: Opportunities and Investments

Article | July 11, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More
MedTech

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 13, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More
Medical

Laboratory Information Management System for Biotech Labs: Significance & Benefits

Article | August 16, 2022

If you have ever visited the testing laboratory of a large biotechnology company, you will be aware that managing the laboratory's operations single-handedly is no easy task. The greater the size of a lab, the more research and testing activities it must accommodate. A variety of diagnostic tests are prescribed for patients in order to detect various diseases. For example, it may include blood glucose testing for diabetics, lipid panel, or liver panel tests for evaluating cardiac risk and liver function, cultures for diagnosing infections, thyroid function tests, and others. Laboratory management solutions such as laboratory information management systems (LIMS) and other software play a significant role in managing various operational data at biotech laboratories. It is one of the important types of software developed to address thedata management and regulatory challenges of laboratories. The software enhances the operational efficiency of biotech labs by streamlining workflows, proper record-keeping, and eradicating the need for manually maintaining data. What Are the Benefits of Laboratory Information Management Software in Biotechnology? As the trends of digitization and technology continue to create deeper inroads into the biotechnology sector, a significant rise in the adoption of innovative medical software solutions, such as LIMS, is being witnessed for managing research data, testing reports, and post-research results globally. Here are a few reasons that are encouraging biotech facilities to adopt LIMS solutions Real-Time Data Collection and Tracking Previously, collecting and transporting samples was a tedious and time-consuming task. However, the adoption of LIMS with innovative tracking modules has made the job easier. The real-time sample tracking feature of LIMS has made it possible for personnel to collect the research data in real-time and manage and control the workflow with a few mouse clicks on the screen. Increase Revenue LIMS makes it possible to test workflows while giving users complete control over the testing process. A laboratory is able to collect data, schedule equipment maintenance or upgrades, enhance operational efficiency, and maintain a lower overhead with the help of the LIMS, thereby increasing revenue. Streamlined Workflow With its completion monitoring, LIMS speeds up laboratory workflows and keeps track of information. It assigns tasks to the specialist along with keeping a real-time track of the status and completion of each task. LIMS is integrated into the laboratory using lab information, which ultimately speeds up internal processes and streamlines the workflow. Automatic Data Exchange LIMS solutions store data in a centralized database. Automated transfer of data between departments and organizations is one of the major features of LIMS. Through its automated information exchange feature, LIMS improves internal operations, decreases the reporting time for data sharing, and assists in faster decision-making. Final Thoughts As the healthcare sector continues to ride the wave of digital transformation, biotech laboratories are emphasizing adopting newer technologies to keep up with the changes. Citing this trend, laboratory information management systems are becoming crucial for biotech and medical organizations for maintaining research data, instant reporting, and managing confidential, inventory, and financial data with centralized data storage.

Read More

Spotlight

Drug Discovery Center of Innovation

The Drug Discovery Center of Innovation (DDCOI) provides pharmaceutical expertise and project management resources to accelerate the translation of discoveries into therapeutics. We offer a non-profit alternative to more traditional approaches to early drug development, with a focus on cost-efficient execution of development tasks, rather than the creation of infrastructure. Our deep pharmaceutical development experts establish and manage project plans, and provide end-to-end data analysis and troubleshooting to facilitate the creation of a successful application for IND and beyond.

Related News

Neurocrine Biosciences and Xenon Launch Up-to-$1.7B Epilepsy, Neuroscience Collaboration

GEN | December 02, 2019

Neurocrine Biosciences has agreed to exclusively license and co-develop Xenon Pharmaceuticals’ Phase I epilepsy candidate XEN901 as a treatment for children—as well as develop three preclinical compounds, the companies said today—through a collaboration that could generate up to $1.7 billion for Xenon. XEN901 is designed as a highly selective Nav1.6 sodium channel inhibitor being developed to treat children with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy. Xenon has completed a Phase I trial of a powder-in-capsule formulation of XEN901 in healthy adults. However, Xenon has also developed a pediatric-specific, granule formulation of XEN901, and has completed juvenile toxicology studies intended to support pediatric development of the drug candidate. “With its proven expertise in developing and commercializing treatments for neurological disorders, we believe Neurocrine Biosciences is an ideal partner to maximize the potential value of XEN901 for patients,” Xenon CEO Simon Pimstone, MD, PhD, FRCPC, said in a statement.

Read More

Machine Learning Harnessed To Build Map of the Connectome

Technology Networks | November 08, 2019

The brain is considered to be one of the most complex systems in existence. And while significant headway has been made to understand it, we tend to generate more questions than answers. But now a research team led by Kyoto University has developed a machine learning model that allows scientists to reconstruct neuronal circuitry by measuring signals from the neurons themselves. The model has the potential to elucidate the difference in neuronal computation in different brain regions. To comprehend the brain, we must look at the neurons that construct it. Our entire world of perception runs across these billions of cells in our head. And that is compounded by the exponentially larger number of connections -- known as synapses -- between them, making the path to our understanding a challenge. Shigeru Shinomoto from Kyoto University's School of Science, who headed the project, explains that although it is possible to record the activity of individual neurons in the brain -- and that number has increased dramatically over the last decade -- it is still a challenge to map out how each of these cells connects to each other.

Read More

UK Scientists Speed up Brain Cancer Diagnosis with AI

Labiotech.eu | November 05, 2019

A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people suspected of having brain tumors. The researchers used an existing technique called infrared spectroscopy to screen 20,000 chemicals in their blood, and then used AI to identify the chemicals that signal a brain tumor. The test correctly identified 82% of the patients that would go on to be diagnosed with brain cancer. Patients flagged with this brain cancer test can be prioritized for confirmatory brain scans, and their diagnosis might take just two weeks. In current practice, it’s difficult to diagnose tumors from patients’ symptoms, and the process can take up to two months, with multiple visits to the doctor. The blood test is being developed by Brennan’s collaborator, the UK company ClinSpec Diagnostics. While other groups are working on cancer tests using infrared spectroscopy and AI, ClinSpec’s test is the most advanced, according to Brennan.

Read More

Neurocrine Biosciences and Xenon Launch Up-to-$1.7B Epilepsy, Neuroscience Collaboration

GEN | December 02, 2019

Neurocrine Biosciences has agreed to exclusively license and co-develop Xenon Pharmaceuticals’ Phase I epilepsy candidate XEN901 as a treatment for children—as well as develop three preclinical compounds, the companies said today—through a collaboration that could generate up to $1.7 billion for Xenon. XEN901 is designed as a highly selective Nav1.6 sodium channel inhibitor being developed to treat children with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy. Xenon has completed a Phase I trial of a powder-in-capsule formulation of XEN901 in healthy adults. However, Xenon has also developed a pediatric-specific, granule formulation of XEN901, and has completed juvenile toxicology studies intended to support pediatric development of the drug candidate. “With its proven expertise in developing and commercializing treatments for neurological disorders, we believe Neurocrine Biosciences is an ideal partner to maximize the potential value of XEN901 for patients,” Xenon CEO Simon Pimstone, MD, PhD, FRCPC, said in a statement.

Read More

Machine Learning Harnessed To Build Map of the Connectome

Technology Networks | November 08, 2019

The brain is considered to be one of the most complex systems in existence. And while significant headway has been made to understand it, we tend to generate more questions than answers. But now a research team led by Kyoto University has developed a machine learning model that allows scientists to reconstruct neuronal circuitry by measuring signals from the neurons themselves. The model has the potential to elucidate the difference in neuronal computation in different brain regions. To comprehend the brain, we must look at the neurons that construct it. Our entire world of perception runs across these billions of cells in our head. And that is compounded by the exponentially larger number of connections -- known as synapses -- between them, making the path to our understanding a challenge. Shigeru Shinomoto from Kyoto University's School of Science, who headed the project, explains that although it is possible to record the activity of individual neurons in the brain -- and that number has increased dramatically over the last decade -- it is still a challenge to map out how each of these cells connects to each other.

Read More

UK Scientists Speed up Brain Cancer Diagnosis with AI

Labiotech.eu | November 05, 2019

A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people suspected of having brain tumors. The researchers used an existing technique called infrared spectroscopy to screen 20,000 chemicals in their blood, and then used AI to identify the chemicals that signal a brain tumor. The test correctly identified 82% of the patients that would go on to be diagnosed with brain cancer. Patients flagged with this brain cancer test can be prioritized for confirmatory brain scans, and their diagnosis might take just two weeks. In current practice, it’s difficult to diagnose tumors from patients’ symptoms, and the process can take up to two months, with multiple visits to the doctor. The blood test is being developed by Brennan’s collaborator, the UK company ClinSpec Diagnostics. While other groups are working on cancer tests using infrared spectroscopy and AI, ClinSpec’s test is the most advanced, according to Brennan.

Read More

Events